Bibliography for: "Sanofi plans counterbid for Zentiva"

"Sanofi plans counterbid for Zentiva". MondayMorning. FindArticles.com. 22 Dec, 2009. http://findarticles.com/p/articles/mi_7401/is_24_16/ai_n32057327/

MondayMorning

View more issues:

Articles in June 23, 2008 issue of MondayMorning

• Bernanke calls healthcare spending major challenge
• Biogen wins proxy fight against Icahn
• Biotech drug sales grew 13% in 2007
• In an otherwise dismal week for the sector, Healthways Inc. led advancing issues, rising $1.62, or 5% on the week, to $33.22
• Pfizer get boost after Ranbaxy delays generic Lipitor
• Hospitals, nursing homes and other healthcare providers owed more than $2 billion in U.S. taxes while being paid by Medicare, a report to Congress found
• Sanofi plans counterbid for Zentiva
• Blackstone to buy Apria for $920 million
• UnitedHealth, WellPoint Plummet on Coventry's forecast
• Boston Scientific Corp
• Medecision Inc
• Medicis Pharmaceutical Corp
• Astrazeneca Plc
• GlaxoSmithKline Plc. won approval for its enlarged prostate drug Avodart in combination with Flomax, which is made by Boehringer Ingelheim Pharmaceuticals Inc. and Astellas Pharma Inc
• Weekly stock performance
• U.S. stocks fell the most in a month Friday as Fifth Third Bancorp's dividend cut and worse-than-expected results from FedEx Corp. renewed concern that mortgage losses and a slowing economy will prolong the profit slump
• Tracking the performance of recent initial public offerings in the sector, Triple-S Management Corp. closed Friday at $17.66, up $3.16, or 22%, from its IPO price of $14.50 on December 7, 2007
• Weekly key rates in percent
• Researchers used 5 billion copies of a single immune cell from a man to wipe out signs of his advanced melanoma for more than two years, according to a report in the New England Journal of Medicine
• A team of US scientists has identified a new family of compounds that block the ability of estrogen to stimulate the growth of breast cancer cells
• Men who have surgery for prostate cancer only to see the illness return are more likely to survive if they get radiation therapy than waiting to see how the disease develops, a study found
• Nursing homes, like luxury hotels in travel guides, will soon get ratings for quality and safety, according to Medicare
• About 1,000 potential incidents of fabrication, falsification or plagiarism in scientific research go unreported every year, according to a survey that suggests such misconduct is far more prevalent than suspected
• US regulators told 25 companies and individuals to stop making "fraudulent" claims that their tablets, teas, tonics, salves and creams may cure cancer and other ailments
• Biotechnology company Alkermes Inc forecast a surprise profit for fiscal 2009, saying part of a payment from Eli Lilly & Co related to its inhaled insulin program would be recognized as revenue in the first quarter, sending its shares up 8% for the
• Pfizer profit plunges 48 percent
• J&J earnings jump on consumer products
• UnitedHealth profit rises on government plans
• Dynacq Healthcare Inc. led advancing issues, more than tripling on the week to $7.93
• Baxter profit surges 39% on vaccines, blood products. financial news
• The Senate Finance Committee, defying a veto threat by President George W. Bush, approved legislation to more than double funding for a U.S. children's health program to $60 billion over five years
• Blackstone unit to buy DJO
• Schering-Plough, Merck profit to rise on cholesterol pill
• Humana Inc
• Abbott Laboratories Inc
• Boston Scientific Corp
• Wyeth Inc.'s
• Cyberonics Inc. won approval for its Demipulse and Demipulse Duo nerve stimulation devices, which treat epilepsy and certain types of depression
• U.S Stocks erased a week of record highs Friday after earnings at Google Inc. and Caterpillar Inc. missed analysts' estimates and banks predicted greater losses from subprime loans
• Included among recent SEC filings for initial public offerings, EnteroMedics Inc. registered up to $86.25 million worth of common stock via J.P. Morgan Securities
• Weekly key rates in percent
• Eli Lilly & Co's osteoporosis drug Evista reduced the risk of certain invasive breast cancers in post-menopausal women, according to a review by US regulators
• Older, less-expensive diabetes drugs are as safe and effective as newer ones, concludes an analysis that bodes well for diabetics and may further hurt sales of Avandia, a blockbuster pill recently tied to heart problems
• Novartis AG, Europe's third-largest drugmaker, cut its 2007 sales-growth forecast because of generic competition and said it plans to buy back $4 billion of stock
• Forest Laboratories Inc's first-quarter profit rose 34% on higher sales of its best-selling drugs, the antidepressant Lexapro and the Alzheimer's treatment Namenda
• Saint Jude Medical Inc , the third-largest maker of implantable electronic heart devices, reported second-quarter profit that beat analysts' estimates because sales of defibrillators surged